Literature DB >> 16403440

Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss.

Ke-Hong Ding1, Zai-Zhao Wang, Mark W Hamrick, Zhong-Bin Deng, Li Zhou, Baolin Kang, Sheng-Li Yan, Jin-Xiong She, David M Stern, Carlos M Isales, Qing-Sheng Mi.   

Abstract

The mechanisms underlying diabetes-mediated bone loss are not well defined. It has been reported that the advanced glycation endproducts (AGEs) and receptor for AGEs (RAGEs) are involved in diabetic complications. Here, mice deficient in RAGE were used as a model for investigating the effects of RAGE on bone mass. We found that RAGE-/- mice have a significantly increased bone mass and bone biomechanical strength and a decreased number of osteoclasts compared to wild-type mice. The serum levels of IL-6 and bone breakdown marker pyridinoline were significantly decreased in RAGE-/- mice. RAGE-/- mice maintain bone mass following ovariectomy, whereas wild-type mice lose bone mass. Furthermore, osteoclast-like cells do express RAGE mRNA. Our data therefore indicate that RAGE serves as a positive factor to regulate the osteoclast formation, directly implicates a role for RAGE in diabetes-promoted bone destruction, and documents that the AGE-RAGE interaction may account for diabetes associated bone loss.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16403440     DOI: 10.1016/j.bbrc.2005.12.107

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  46 in total

1.  Arterial calcification is driven by RAGE in Enpp1-/- mice.

Authors:  Denise L Cecil; Robert A Terkeltaub
Journal:  J Vasc Res       Date:  2010-11-23       Impact factor: 1.934

2.  Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells.

Authors:  Natalia Mercer; Hafiz Ahmed; Susana B Etcheverry; Gerardo R Vasta; Ana Maria Cortizo
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

3.  Accumulation of carboxymethyl-lysine (CML) in human cortical bone.

Authors:  Corinne J Thomas; Timothy P Cleland; Grazyna E Sroga; Deepak Vashishth
Journal:  Bone       Date:  2018-02-02       Impact factor: 4.398

4.  Bone fragility in type 2 diabetes mellitus.

Authors:  Toru Yamaguchi
Journal:  World J Orthop       Date:  2010-11-18

Review 5.  Bone and the innate immune system.

Authors:  Julia F Charles; Mary C Nakamura
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

6.  Chronic hyperglycemia affects bone metabolism in adult zebrafish scale model.

Authors:  Marta Carnovali; Livio Luzi; Giuseppe Banfi; Massimo Mariotti
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

Review 7.  Diabetes and Its Effect on Bone and Fracture Healing.

Authors:  Hongli Jiao; E Xiao; Dana T Graves
Journal:  Curr Osteoporos Rep       Date:  2015-10       Impact factor: 5.096

8.  Spontaneous bone loss in RIP-iNOS transgenic mouse: a mouse model for diabetes-mediated osteopenia/osteoporosis.

Authors:  Qing-Sheng Mi; Sheng-Li Yan; Zai-Zhao Wang; Ke-Hong Ding; Changgui Li; Luan Wang; Li Zhou; Yasuhiko Yamamoto; Hiroshi Yamamoto; Hiroshi Okamoto; Carlos Isales
Journal:  Cell Cycle       Date:  2009-12-21       Impact factor: 4.534

Review 9.  Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.

Authors:  M Saito; K Marumo
Journal:  Osteoporos Int       Date:  2010-02       Impact factor: 4.507

10.  Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes.

Authors:  Masahiro Yamamoto; Toru Yamaguchi; Mika Yamauchi; Toshitsugu Sugimoto
Journal:  Diabetes Care       Date:  2009-09-14       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.